There is evidence that resistin increases aggressiveness in breast cancer, favoring processes such as tumor growth by increasing BCL-2 and BCL-xL activity, accompanied by a decrease in cleaved caspase-7 and -3. This evidence concerns the gene BCL2 and breast carcinoma.